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Abstract
Background Autophagy enables cells to digest endoge-
nous/exogenous waste products, thus potentially prolong-
ing the cellular lifespan. Early endothelial progenitor cells
(eEPCs) protect mice from ischemic acute kidney injury
(AKI). The mid-term prognosis in AKI critically depends
on vascular rarefication and interstitial fibrosis with the
latter partly being induced by mesenchymal transdifferen-
tiation of endothelial cells (EndoMT). This study aimed to
determine the impact of eEPC preconditioning with dif-
ferent autophagy inducing agents [suberoylanilide
hydroxamic acid (SAHA)/temsirolimus] in ischemic AKI.
Methods Male C57/Bl6 N mice were subjected to bilat-
eral renal ischemia (40 min). Animals were injected with
either untreated, or SAHA- or temsirolimus-pretreated
syngeneic murine eEPCs at the time of reperfusion. Mice
were analyzed 48 h and 4 weeks later. In addition, cultured
eEPCs were treated with transforming growth factor
(TGF)-b ± SAHA, autophagy (perinuclear LC3-II), and
stress-induced premature senescence (SIPS—senescence-
associated b-galactosidase, SA-b-Gal), and were evaluated
96 h later.
Results Cultured eEPCs showed reduced perinuclear
density of LC3-II ? vesicles and elevated levels of SA-b-
Gal after treatment with TGF-b alone, indicating impaired
autophagy and aggravated SIPS. These effects were com-
pletely abrogated by SAHA. Systemic administration of
either SAHA or tems pretreated eEPCs resulted in elevated
intrarenal endothelial p62 at 48 h and 4 weeks, indicating
stimulated endothelial autophagy. This effect was most
pronounced after injection of SAHA-treated eEPCs. At
4 weeks endothelial expression of mesenchymal alpha-
smooth muscle actin (aSMA) was reduced in animals
receiving untreated and SAHA-pretreated cells. In addi-
tion, SAHA-treated cells reduced fibrosis at week 4. Tems
in contrast aggravated EndoMT. Postischemic renal func-
tion declined after renal ischemia and remained unaffected
in all experimental cell treatment groups.
Conclusion In ischemic AKI, intrarenal endothelial
autophagy may be stabilized by systemic administration of
pharmacologically preconditioned eEPCs. Early EPCs can
reduce postischemic EndoMT and fibrosis in the mid-term.
Autophagy induction in eEPCs either increases or decrea-
ses the mesenchymal properties of intrarenal endothelial
cells, depending on the substance being used. Thus,
endothelial autophagy induction in ischemic AKI, medi-
ated by eEPCs is not a renoprotective event per se.
Keywords AKI  Endothelial autophagy  EPCs 
EndoMT
Introduction
Early endothelial progenitor (or outgrowth) cells (eEPCs/
eEOCs) have been proven as an effective therapeutic tool
in murine ischemic acute kidney injury (AKI) [1, 2]. As
opposed to so-called late EPCs (lEPCs), early EPCs pre-
dominantly act by indirect mechanisms (e.g., modulation of
the perivascular milieu by producing proangiogenic sub-
stances and/or by releasing vasoprotective microparticles,
enriched by certain micro-RNA molecules). In the current
literature, lEPCs are defined as true progenitors of
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endothelial cells whereas eEPCs are classified as ‘he-
matopoietic cells with proangiogenic activity’. Neverthe-
less, early EPCs have successfully been used to treat
ischemic diseases under diverse experimental conditions
(e.g., ischemic heart and cerebrovascular disease). In 2006,
the cells were shown to promote post-AKI repair as well.
Meanwhile, a significant number of pharmacological
strategies have been established, helpful to increase reno-
protective competence of eEPCs in ischemic AKI [3–7].
The microenvironmental alterations associated with
ischemia can significantly aggravate renal damage since
ischemia does not only induce tubular malfunction/damage
but also interstitial inflammation and severe microvascu-
lopathy [8]. The latter causes ongoing ischemia even if the
initial cause of hypoperfusion has been eliminated. Both
postischemic interstitial inflammation and microvascu-
lopathy significantly result from alterations of the para-
crinic milieu. The proximal tubule releases numerous
factors including tumor necrosis factor (TNF)-a, inter-
leukin (IL)-6, IL-1b, TGF-b, monocyte chemoattractant
protein-1 [MCP-1], IL-8, and RANTES [9–11]. In such a
context, mature endothelial cells undergo aggravated
senescence or stress-induced premature senescence (SIPS)
[12]. eEPCs, after invading the kidney via the renal artery,
are most likely also altered by deleterious effects of diverse
humoral factors and it can be argued that SIPS decreases
the anti-ischemic competence of eEPCs in AKI. A few
years ago, studies by the group of Goligorsky elegantly
showed a dynamic cascade of hyperglycemia-induced
inhibition of endothelial autophagy, followed by increased
endothelial SIPS [13]. Autophagy is widely regarded as an
endogenous defense mechanism against numerous
endogenous and exogenous stressors. The role of autop-
hagy in modulating the ‘renal injury-response’ has espe-
cially been analyzed in the tubular compartment.
Periyasamy-Thandavan and colleagues identified autop-
hagy as a cytoprotective mechanism in cisplatin-induced
damage of proximal tubular epithelial cells [14]. Another
study showed autophagy to have a protective role during
in vitro hypoxia and in vivo ischemia–reperfusion injury
(IRI) [15]. Finally, Quercetin-mediated attenuation of renal
IRI was shown to critically depend on autophagy activation
in an AMP-activated protein kinase-dependent manner
[16]. Therefore one may conclude that stimulated (tubular)
autophagy generally increases tissue resistance against
toxic/ischemic damage. Nevertheless, de facto no study has
so far evaluated the role of endothelial autophagy in AKI.
Thus, the aim of our study was to analyze whether stabi-
lization of autophagy in therapeutically administered




The animal study protocol was in accordance with the
guidelines of the German Institute of Health Guide for
the Care and Use of Laboratory Animals and ap-proved
by the Institutional Animal Care and Use Committee.
C57BL/6 N mice were originally obtained from Jack-
son Labs (Bar Harbor, ME, USA) and bred in the local
animal facility of the Go¨ttingen University Hospital.
As in previous studies, male 8-12 week-old C57Bl/6 N
mice were used in all experiments. All animals were
separately caged with a 12:12-h light–dark cycle and
had free access to water and chow throughout the
study.
Surgical procedures
Mice were anesthetized (300 ll of 6 mg/100 g ketamine
hydrochloride plus 0.77 mg/100 g xylazine hydrochlo-
ride) and placed on a heated surgical pad. Rectal tem-
perature was maintained at 37 C. After a 1.5-cm mid-
laparotomy, the right kidney was removed. The left
kidney was exposed and clamping of the renal pedicle
was performed with microserrefines (Fine Science Tools,
Foster City, CA, USA). For induction of AKI, we per-
formed unilateral renal artery clamping post-
uninephrectomy. The respective procedure has been used
in several earlier studies [4, 17, 18]. Briefly, first, a
suture was placed around the right renal artery, vein, and
ureter, respectively. The suture was held open until cell
injection. Simultaneously, the left renal pedicle was
transiently (40 min) occluded. At the end of the ischemic
period a certain volume of eEPC-containing EBM-2
media (0.5 9 106 eEOCs in 100 ll) was injected into the
right renal vein (systemic circulation). Very shortly after
cell injection, the suture was closed in order to prevent
bleeding. The kidney was removed afterwards. AKI
resulted from transient occlusion of the left renal pedi-
cle, followed by contralateral nephrectomy. The
abdominal incision was closed with a 4–0 suture and
surgical staples. In each experimental group 10 animals
were analyzed. Animals were sacrificed at hour 48 or at
week 4 postischemia. The experimental conditions were
chosen since earlier studies showed that AKI cannot be
prevented if 0.5 9 106 eEPCs are administered after
acute renal ischemia of 40 min. Thus, these were optimal
conditions to test the hypothesis that endothelial autop-
hagy stabilization may improve postischemic kidney
function.
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Culture of mouse-derived early endothelial
progenitor cells
In order to perform cell injection experiments eEPCs were
isolated from C57Bl/6 N mice as described previously [17,
19]. Briefly, mouse mononuclear cells (MNCs) were enri-
ched by density gradient centrifugation using Biocoll
solution (Biochrom, Berlin, Germany) from peripheral
blood and spleen cell extracts. The reason for pooling
MNCs was to maximize the total number of cells available
for injection. Immediately following isolation, MNCs were
mixed and 4 9 106 cells were plated on 24-well culture
dishes coated with human fibronectin (Sigma, St Louis,
MO, USA) and maintained in endothelial cell growth
medium-2 (EGM-2 - Clonetics, Lonza, Walkersville, MD,
USA) supplemented with EGM single-quots containing
5 % fetal calf serum (FCS). After 4–5 days of culture,
eEPCs were identified by the uptake of DiI-labeled acety-
lated low density lipoprotein (acLDL) (Invitrogen, Carls-
bad, CA, USA) and binding of FITC-labeled BS-1 lectin
(BS-1) (Sigma Diagnostics, St. Louis, MO, USA). For
in vitro cell experiments, a murine endothelial progenitor
cell line was purchased (66110-37—Celprogen stem cell
research and therapeutics, San Pedro, CA, USA) and cul-
tured according to the manufacturer’s protocol. Pharma-
cological preconditioning was performed using either
suberoylanilide hydroxamic acid (SAHA) or temsirolimus
at the following concentrations: SAHA (5 lmol), tem-
sirolimus (10 lg/ml). Cell incubation was performed in
EGM for 1 h at 37 C. After washing the cells with EGM,
0.5 9 106 eEPCs were resuspended in 100 ll EGM for
systemic injection.
Cell culture experiments
Primary murine endothelial progenitor cells (MEPC—
Celprogen, 66110-37) were incubated with either SAHA
alone (5 lmol) or with SAHA and TGF-b (5 ng/ml)
combined for 1 h at 37 C. Treatments were performed in
EGM. After washing the cells, LC3-II was stained with
anti-LC3 rabbit (Cell Signaling, 2775), followed by sec-
ondary incubation with anti-rabbit IgG-NL 493 (NL006,
R&D Systems, Minneapolis, MN, USA). Primary incuba-
tion was performed overnight at 4 C while secondary
incubation was performed for 1 h at room temperature.
Staining of senescence-associated beta-galactosidase (SA-
b-Gal) was performed using a commercially available kit
(Signaling, 9860) according to the manufacturer´s protocol.
Autophagy was quantified by measuring the density of
LC3? perinuclear vesicles using ImageJ software. SIPS
was quantified by measuring the cell surface area covered
by blue staining signals (%) (ImageJ).
Histology including immunofluorescence of tissue
sections
For quantification of kidney fibrosis, formalin-fixated,
paraffin-embedded tissue sections were stained with Mas-
son Trichrome. The amount of collagen deposition was
assed using ImageJ software. Fibrosis was given as the
mean percentage of three view fields covered by the color
green. For evaluating EndoMT, formalin-fixated, paraffin-
embedded tissue sections were stained with rat anti-mouse
CD31 (PECAM-1—CloneSZ31, Dianova) and rabbit anti-
SMA (EMELCA) for primary incubation and with Alexa
Fluor 488 goat anti-rabbit IgG (Dianova) and Alexa Fluor
594 goat anti-rat IgG (Dianova) for secondary incubation.
Primary incubation was performed overnight at 4 C while
secondary incubation was performed for 1 h at room
temperature. In accordance with a more recent publication
about methodological approaches for autophagy visual-
ization, p62 and not LC3-II was used for detecting
autophagocytic activity in tissue sections [20]. Staining of
p62 was performed with rabbit anti p62 (abcam ab91526)
for primary incubation (4 C, overnight), followed by
secondary incubation with anti-rabbit 488 (Jackson
ImmunoResearch, West Grove, PA, USA) for 1 h at RT.
To visualize the nuclei, tissue sections were counterstained
with DAPI. Three view fields per kidney were analyzed for
colocalization of either aSMA or p62 and CD31 using
ImageJ software.
Analysis of renal function
Serum creatinine concentration was measured using a
commercially available kit (Creatinin, Jaffe´, Labor und
Technik, Eberhard Lehmann, LT-CR0121, Berlin, Ger-
many) according to the manufacturer’s protocol.
Statistical analysis
The results were expressed as mean ± standard error of the
mean (SEM). The means of two populations were com-
pared by Student’s t test or Mann–Whitney U test. Dif-
ferences were considered significant at p\ 0.05.
Results
Pharmacological autophagy activation reduces SIPS
in cultured early endothelial progenitor cells
The first experiments were related to the dynamics of
autophagy and SIPS in cultured murine eEPCs. In order to
induce SIPS, cells were treated with TGF-b. SIPS was
J Nephrol (2016) 29:637–644 639
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evaluated by staining the cells for SA-b-Gal (% of cell
surface area stained positive). TGF-b treatment resulted in
increased SA-b-Gal positivity after 96 as compared to
24 h: 96 h 57.4 ± 7.1 % vs. 24 h 31.4 ± 4.4 %. The dif-
ference was close to the level of significance (p = 0.06).
Next, cells were coincubated with TGF-b and the autop-
hagy inducing substance SAHA. At 24 h, SA-b-Gal posi-
tivity was 45.8 ± 5.4 %. The difference between SAHA
and non-SAHA treated cells was not significant at this time
(p = 0.18). At 96 h, in contrast, SA-b-Gal was markedly
reduced as compared to 24 h (?SAHA) and as compared to
96 h without SAHA coincubation: 96 h ?SAHA
17.3 ± 3.4 % vs. 24 h ?SAHA 45.8 ± 5.4 % and vs. 96 h
-SAHA 57.4 ± 7.1 %, p = 0.02 and p = 0.02) (Fig. 1).
In order to analyze autophagy, cells were stained for LC3-
II. Autophagocytic activity was quantified by measuring
the density of perinuclear LC3-II? vesicles (perinuclear
granularity, PN, arbitrary units). Without SAHA, TGF-b
induced a significant PN decrease from hour 24 to hour 96:
24 h 0.6 ± 0.1 vs. 96 h 0.24 ± 0.07, p = 0.03. SAHA
coincubation in contrast stabilized PN from hour 24 to 96:
24 h ?SAHA 0.58 ± 0.26 vs. 96 h ?SAHA 0.71 ± 0.33,
p = 0.77 (Fig. 1).
Preconditioned eEPCs stimulate autophagy
in intrarenal endothelial cells
Next, we aimed to analyze whether systemic administration
of preconditioned eEPCs to postischemic mice would
modulate autophagy in mature endothelial cells of smaller
arteries/arterioles. Cell preconditioning was performed
using two different autophagy inducing agents, the sub-
stance SAHA and the mammalian target of rapamycin
(mTOR) inhibitor temsirolimus. Endothelial autophagy
was measured by staining of p62 in CD31? cells, and
analyzed at 48 h and 4 weeks postischemia. The results
shall be given separately for 48 h and 4 weeks. At 48 h
(p62 in CD31? cells in %): Control 4.5 ± 1.1 %, IRI
13.1 ± 2.5 %, IRI?eEPCs 18.6 ± 2.7 %, IRI?eEPCs?-
SAHA 34.5 ± 7.6 %, IRI?eEPCs?temsirolimus 18 ±
2.8 %. The following differences were significant: Control
vs. IRI (p = 0.0051) vs. IRI?eEPCs (p = 0.001) vs.
A1
A2 A3 A4 A5
B1
B2 B3 B4 B5
Fig. 1 Autophagy and SIPS in cultured murine eEPCs exposed to
TGF-b with vs. without SAHA treatment. a.1 Shows time-courses of
cellular autophagy, as reflected by the perinuclear density (PN) of
LC3-II? vesicles. TGF-b alone decreased PN from hour 24 to 96,
SAHA completely stabilized PN. a.2–a.5 Representative images of
LC3-II stained cells with vs. without SAHA treatment (magnifica-
tion 9100). b.1 Displays dynamics of cellular SIPS with decreased
SA-b-Gal positivity at hour 96 after combined incubation with TGF-b
and SAHA. Representative images of SA-b-Gal stained cells are
shown in images b.2–b.5 (magnification 940) (data as mean ± SEM,
*p\ 0.05). eEPCs, early endothelial progenitor cells; TGF, trans-
forming growth factor; SAHA, suberoylanilide hydroxamic acid;
SIPS, stress-induced premature senescence
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IRI?eEPCs?SAHA (p\ 0.0001) vs. IRI?eEPCs?tem-
sirolimus (p\ 0.0001); IRI vs. IRI?eEPCs (p = 0.028)
vs. IRI?eEPCs?SAHA (p = 0.0032) vs. IRI?eEPCs?
temsirolimus (p = 0.047); IRI?eEPCs vs. IRI?
eEPCs?SAHA (p = 0.033). At 4 weeks: IRI 13.4 ±
1.7 %, IRI?eEPCs 21 ± 2.3 %, IRI?eEPCs?SAHA
27.3 ± 2.4 %, IRI?eEPCs?temsirolimus 18.5 ± 3.2 %.
The following differences were significant: Control vs. IRI
(p = 0.0017) vs. IRI?eEPCs (p = 0.0003) vs. IRI?
eEPCs?SAHA (p\ 0.0001) vs. IRI?eEPCs?tem-
sirolimus (p = 0.00017); IRI vs. IRI?eEPCs (p = 0.023)
vs. IRI?eEPCs?SAHA (p = 0.0029) (Fig. 2).
Preconditioned eEPCs fail to improve postischemic
kidney function in the short- and mid-term
Excretory kidney function was significantly affected in all
postischemic mice. At 48 h (serum creatinine in mg/dl):
Control 0.28 ± 0.01, IRI 0.59 ± 0.03, IRI?eEPCs
0.49 ± 0.02, IRI?eEPCs?SAHA 0.58 ± 0.02, IRI?
eEPCs?temsirolimus 0.49 ± 0.03. At 4 weeks: IRI
0.47 ± 0.02, IRI?eEPCs 0.47 ± 0.02, IRI?eEPCs
?SAHA 0.5 ± 0, IRI?eEPCs?temsirolimus 0.47 ± 0.01.
The p-values were: Control vs. IRI 48 h (p\ 0.0001) vs.
IRI?eEPCs 48 h (p\ 0.00t01) vs. IRI?eEPCs?SAHA
48 h (p\ 0.0001) vs. IRI?eEPCs?temsirolimus 48 h
(p = 0.00053) vs. IRI 4 weeks (p\ 0.0001) vs.
IRI?eEPCs 4 weeks (p\ 0.0001) vs. IRI?eEPCs?SAHA
4 weeks (p\ 0.0001) vs. IRI?eEPCs?temsirolimus
4 weeks (p\ 0.0053). Finally, administration of uncondi-
tioned and temsirolimus pretreated eEPCs improved kid-
ney function at 48 h: IRI vs. IRI?eEPCs (p = 0.019) vs.
IRI?eEPCs?temsirolimus (p = 0.037) (Fig. 3).
Native and preconditioned eEPCs mediate
antimesenchymal effects in the mid-term
Endothelial-to-mesenchymal transition significantly con-
tributes to tissue fibrosis in the kidney and in other organs
such as the heart [19, 21, 22]. Fibrosis was analyzed by
Masson trichrome staining, the results being expressed in
relative units. At 48 h: Control 0.27 ± 0.06, IRI
0.33 ± 0.09, IRI?eEPCs 0.53 ± 0.18, IRI?eEPCs?










































































































Fig. 2 Intrarenal endothelial autophagy after IRI with versus without
systemic administration of unconditioned or preconditioned eEPCs.
a Percentages of endothelial p62 in the short-term (48 h). Endothelial
presence of p62 increased after IRI in all experimental groups.
Administration of unconditioned and preconditioned eEPCs further
elevated p62 with a peak in the ‘eEPC ? SAHA’-group. b Endothelial
p62 at week 4 after IRI. c–j p62 (green) in the endothelium of a small
artery (CD31—red; c–e control, f–h post-IRI at 48 h). Images i and
j magnify the endothelial layer. The white ovals in i and j surround
the endothelium in areas of increased p62 presence (Tems: tem-
sirolimus; magnification in C–H 920, in I and J & 940; Data in A
and B are mean ± SEM, ‘*’ indicates significant differences
(p\ 0.05) as compared to untreated controls, ‘#’ indicates significant
differences as compared to the ‘IRI’-group, ‘?’ indicates the
difference between ‘?eEOCs’ and ‘? eEOCs ? SAHA’—for exact
p-values see text). IRI, ischemia–reperfusion injury; eEOCs, early
endothelial outgrowth cells. For other abbreviations, see previous
figure (color figure online)
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0.17. The differences were not statistically significant at 48
h. Four weeks: IRI 2.9 ± 0.8, IRI?eEPCs 2.6 ± 0.23,
IRI?eEPCs?SAHA 0.36 ± 0.05, IRI?eEPCs?tem-
sirolimus 3.86 ± 0.73. The following differences were sig-
nificant: Control vs. IRI (p\ 0.0001) vs. IRI?eEPCs
(p\ 0.0001) vs. IRI?eEPCs?temsirolimus (p\ 0.0001).
Endothelial-to-mesenchymal transition was evaluated by
tissue staining of aSMA and Cat D31. The results are given
separately for 48 h and 4 weeks. At 48 h (aSMA in CD31?
cells in %): Control 0.8 ± 0.28 %, IRI 2.14 ± 0.42 %,
IRI?eEPCs 3.07 ± 0.49 %, IRI?eEPCs?SAHA 2.18 ±
0.51 %, IRI?eEPCs?temsirolimus 7.3 ± 0.86 %. The fol-
lowing differences were significant: Control vs. IRI
(p = 0.017) vs. IRI?eEPCs (p = 0.0025) vs. IRI?eEPCs
?SAHA (p = 0.0075) vs. IRI?eEPCs?temsirolimus
(p\ 0.0001); IRI?eEPCs?temsirolimus vs. IRI
(p\ 0.0001) vs. IRI?eEPCs (p = 0.003) vs. IRI?eEPCs
?SAHA (p\ 0.0001). At 4 weeks: IRI 4.7 ± 0.4 %,
IRI?eEPCs 1.8 ± 0.6 %, IRI?eEPCs?SAHA 1.65 ±
0.4 %, IRI?eEPCs?temsirolimus 15.8 ± 2.5 %. The fol-
lowing differences were significant: Control vs. IRI
(p\ 0.0001) vs. IRI?eEPCs?temsirolimus (p\ 0.0001);
IRI vs. IRI?eEPCs (p = 0.0037) vs. IRI?eEPCs?
SAHA (p = 0.005); IRI?eEPCs?temsirolimus vs. IRI
(p\ 0.0001) vs. IRI?eEPCs (p = 0.0014) vs. IRI?
eEPCs?SAHA (p\ 0.0001) (Fig. 4).
Discussion
In this study we report consequences of endothelial
autophagy (AP) stabilization in ischemic AKI for the first














































































Fig. 3 Postischemic kidney function in all experimental groups.
Ischemia diminished excretory function until week four. Cell therapy
did not improve serum creatinine levels with one exception (native
eEPCs at 48 h) (Data are mean ± SEM, ‘*’ indicates significant
differences (p\ 0.05) as compared to untreated controls, ‘#’ indicates




Fig. 4 Renal fibrosis and EndoMT in the respective groups. Signif-
icant fibrosis exclusively occurred after 4 weeks but not at 48 h
postischemia (a). Administration of SAHA treated cells mediated
anti-mesenchymal effects at week 4. b EndoMT at 48 h postischemia.
Endothelial cells within small arteries/arterioles displayed increased
expression of alpha-smooth muscle actin in all experimental groups,
the strongest pro-mesenchymal transformation was observed in
animals receiving temsirolimus-treated eEPCs. c EndoMT at week
4 postischemia. While temsirolimus-treated cells further aggravated
EndoMT, administration of native and SAHA preconditioned eEPCs
stabilized endothelial properties of the cells [data as mean ± SEM,
‘*’ indicates significant differences (p\ 0.05) as compared to
untreated controls, ‘#’ in a difference between ‘IRI’ and ‘?eEPCs?-
SAHA 4 w’; ‘#’ in b difference between ‘IRI’ and ‘?eEPCs?Tems’;
‘#’ in c differences as compared to ‘IRI’; ‘?’ in b difference between
‘?eEPCs’ and ‘?eEPCs?Tems’; ‘?’ in c difference between ‘IRI’
and ‘?eEPCs?Tems’; ‘##’ in b difference between ‘?eEPCs?-
SAHA’ and ‘?eEPCs?Tems’–for exact p-values see text]. EndoMT,
mesenchymal transdifferentiation of endothelial cells. For other
abbreviations, see previous figures
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defense mechanism against numerous stressors of exoge-
nous and endogenous origin [20]. Autophagy activation
can prolong the cellular lifespan, depending on the
microenvironmental circumstances that cells are being
exposed to. The role of AP in AKI has been investigated by
several investigators in the past. However, no study ever
evaluated the particular role of endothelial autophagy.
Tubular AP, in contrast, has been the object of interest in
recent years. Chen and colleagues showed attenuation of
renal ischemia/reperfusion injury via activation of the
AMP-activated protein kinase-regulated autophagy path-
way [16]. Another study identified autophagy as a cyto-
protective mechanism during cisplatin injury of renal
proximal tubular cells [14]. Finally, Howell and colleagues
showed autophagy augmentation as an effective approach
to treat acute kidney injury during endotoxemia in mice
[23]. Together, these investigations point towards a pro-
tective role of (tubular) AP in AKI. However, a more
recent and yet unpublished study by Schmitt and col-
leagues (ASN meeting 2014) showed that AP, although
protecting the tubular compartment in the short term, may
aggravate the risk for SIPS in the mid- to long-term, thus
increasing the risk for chronic kidney disease (CKD).
Our data clearly indicate that eEPC autophagy can be
stimulated by pharmacological measures. TGFb-induced
SIPS on the other hand is diminished. Systemic admin-
istration of AP-stimulated eEPCs activates the
autophagocytotic cascade in intrarenal endothelial cells
(small arteries/arterioles). Nevertheless, induced endothe-
lial AP is not associated to any improvement of postis-
chemic renal function either in the short- or in the mid-
term. However, both, native and SAHA-preconditioned
eEPCs inhibit EndoMT in the mid-term and SAHA-trea-
ted cells diminish fibrosis at this time as well. The general
conclusions that may be drawn from the study are: (1)
endothelial autophagy activation (via eEPCs) is not a
renoprotective measure per se. The (pharmacological)
protocol being for used for AP induction is fundamentally
important; (2) although induced endothelial AP is asso-
ciated with reduced EndoMT under certain circumstances,
any mechanistic relationship between the two processes
cannot be proposed at the moment; (3) the autophagy
inducer SAHA enables eEPCs to act as an antifibrotic.
These effects are not exclusively mediated by modulation
of EndoMT since native eEPCs reduced EndoMT as well
but fibrosis did not differ from that in animals receiving
SAHA-preconditioned cells. Organofibrogenesis is a
complex process ultimately resulting in tissue scaring and
dysfunction [24]. Although activated fibroblasts have been
proposed as the major source of collagen/matrix produc-
tion, further cell types have been identified to differentiate
into pro-fibrotic cells under certain circumstances. Among
those are endothelial and smooth-muscle cells, and
pericytes [24]. Finally, tubular epithelial cells in the
kidney may acquire a mesenchymal phenotype (EMT—
epithelial-to-mesenchymal transition) [25]. Early EPCs
modulate the postischemic microenvironment by secreting
a multitude of humoral factors and by releasing vaso-
modulatory microparticles [26–29]. The latter have been
shown to reduce tubular cell apoptosis as well [27] and
possible long-term effects on mesenchymal properties of
tubular (and other types of) cells may be presumed. Most
studies performed in the past failed to show significant
incorporation of eEPCs into the endothelial layer of small
blood vessels, which is in line with the concept of indirect
cell activity within the perivascular compartment. In the
current study we avoided cell tracing using an exogenous
dye. In an older study Celtracker-labelled eEPCs sig-
nificantly deteriorated postischemic kidney function after
being preconditioned with angiopoietin-1. Thus, exoge-
nous tracing strategies may potentially be more harmful
than beneficial.
In summary, a renoprotective role for endothelial AP in
AKI cannot definitely be proposed at the moment.
Endothelial AP may modulate postischemic kidney fibro-
sis, depending on the strategy used for AP induction.
However, the current study has its limitations. Endothelial
autophagy was stimulated by the administration of phar-
macologically preconditioned cells. Those may influence
the biological behavior of other cell types in the kidney as
well. Therefore, we did not use a highly specific strategy
for endothelial autophagy activation. Additional experi-
ments are required to analyze the consequences of
endothelial autophagy activation in a more selective man-
ner (e.g., transgenic organisms displaying autophagy acti-
vation in exclusively endothelial cells). Such studies are on
the way. The current investigation was designed as a pilot
study intended principally to prove or to exclude postis-
chemic renoprotection after endothelial autophagy activa-
tion. By using a transgenic model, functional and structural
alterations of the tubular compartment would exclusively
occur as a result of modulated endothelial autophagy.
Conclusion
A renoprotective role for endothelial autophagy in AKI
cannot definitely be proposed. Endothelial autophagy may
modulate postischemic kidney fibrosis, depending on the
strategy used for AP induction.
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